Flint launched on October 21, 2026. It is a 40-billion-parameter model built specifically for coding work. On a MacBook Pro with an M4 Pro chip, Flint generates over 125 tokens per second. On RTX ...

The stock of Recursion Pharmaceuticals (RXRX) has gained >15% in early trading today, as the AI-driven drug discovery company shared a couple of notable updates. Firstly Recursion announced the ...

This post originally appeared on the Christensen Institute’s blog and is reposted here with permission. In a TED Talk viewed over 2 million times, Efosa Ojomo of the Christensen Institute made the ...

In March of 2026, the FDA finalized a rule requiring Big Pharma and startups alike to switch to a uniform 12-digit code by 2033. While it may appear to be a routine regulatory update, the change ...

“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...

How do you get from a chatbot that sometimes makes things up to a machine that humans might struggle to control? There are several steps in that argument, and plenty of uncertainty. But an idea known ...

U.S. investors could soon get the chance to pile into a pure-play robotics company that said it just achieved a big breakthrough in the world of humanoids — as it seeks to improve its financial ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.

On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...